REG - ReNeuron Group plc - Directorate Change
RNS Number : 0263SReNeuron Group plc12 March 2021ReNeuron Group plc
("ReNeuron" or the "Company")
Directorate change
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that Michael Hunt, an executive director of the Company and its current Chief Financial Officer, has yesterday resigned from the Company in order to pursue other projects. Mr Hunt joined the Board in early 2001 and will remain with the Company until the end of May to facilitate an orderly transition to his successor, when appointed. The Company has initiated a search for Mr Hunt's replacement and a further announcement will be made in due course.
Mr Hunt commented:
"After twenty years at the Company, and with the business now in a much stronger financial position, it is the right time for me to move on to new challenges. I am proud to have contributed to ReNeuron's progression to be one of the leading players in the gene and cell therapy sector, and I wish the Company and colleagues every future success."
Olav Hellebø, Chief Executive Officer, commented:
"With tenures over the years as both CFO and CEO of the Company, Michael has played a key role in the development of ReNeuron into the exciting business that it is today. On behalf of ReNeuron, I would like to thank Michael for his very significant contribution to the Company and wish him well in his future endeavours."
ENDS
Contacts:
ReNeuron
Olav Hellebø, Chief Executive Officer
Via Walbrook PR
Michael Hunt, Chief Financial Officer
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
Ben Maddison, Stewart Wallace
+44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker)
+44 (0)20 3328 5656
James Reeve/George Payne (Corporate Finance)
Tim Sohal (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations)
+44 (0)20 7933 8780 or reneuron@walbrookpr.com
Paul McManus, Alice Woodings
+44 (0)7980 541 893 / +44 (0)7407 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDBOABIGDXSSBDGBB
Recent news on ReNeuron
See all newsREG - FTSE Russell - ReNeuron Group
AnnouncementREG - ReNeuron Group plc - Appointment of Administrators
AnnouncementREG - ReNeuron Group plc - Intention to Appoint Administrators
AnnouncementREG - ReNeuron Group plc - Block Listing Review & Total Voting Rights
AnnouncementREG - AIM ReNeuron Group plc - Suspension - ReNeuron Group plc
Announcement